Qiagen (NYSE:QGEN) Stock Jumps 7.7% – Time to Buy?

Shares of Qiagen N.V. (NYSE:QGEN) rose 7.7% on Friday. The stock traded as high as $45.00 and last traded at $45.2920. Approximately 1,586,694 shares traded hands during trading, a decline of 36% from the average session volume of 2,469,240 shares. The stock had previously closed at $42.04.

Analyst Upgrades and Downgrades

QGEN has been the topic of several recent research reports. Stifel Nicolaus set a $40.00 price objective on Qiagen in a research report on Friday, August 7th. Barclays set a $40.00 target price on shares of Qiagen and gave the company an “equal weight” rating in a research note on Friday, August 7th. Morgan Stanley restated an “overweight” rating on shares of Qiagen in a research report on Friday, September 11th. Kepler Capital Markets set a $38.60 price objective on shares of Qiagen and gave the company a “hold” rating in a report on Thursday, June 25th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $48.00 price objective on shares of Qiagen in a research report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, Qiagen currently has a consensus rating of “Hold” and a consensus price target of $43.51.

Qiagen Price Performance

The company has a quick ratio of 2.31, a current ratio of 2.85 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $9.26 billion, a PE ratio of 23.01, a PEG ratio of 4.36 and a beta of 0.61. The stock has a 50-day moving average price of $43.03 and a 200 day moving average price of $39.93.

Qiagen (NYSE:QGEN) last announced its earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.60 by $0.02. Qiagen had a return on equity of 14.47% and a net margin of 19.49%.The firm had revenue of $535.04 million for the quarter, compared to analyst estimates of $527.50 million. During the same quarter last year, the firm posted $0.60 EPS. The business’s revenue was up .2% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.430- EPS. Equities analysts forecast that Qiagen N.V. will post 2.43 EPS for the current fiscal year.

Institutional Trading of Qiagen

Several institutional investors have recently modified their holdings of the stock. State Street Corp lifted its stake in Qiagen by 4.5% in the 2nd quarter. State Street Corp now owns 2,183,206 shares of the company’s stock valued at $85,363,000 after buying an additional 93,575 shares in the last quarter. Sequoia Financial Advisors LLC purchased a new stake in Qiagen during the 2nd quarter worth approximately $252,000. WINTON GROUP Ltd acquired a new position in shares of Qiagen during the second quarter valued at approximately $1,423,000. Engineers Gate Manager LP raised its holdings in shares of Qiagen by 107.7% during the second quarter. Engineers Gate Manager LP now owns 74,567 shares of the company’s stock valued at $2,916,000 after acquiring an additional 38,658 shares during the last quarter. Finally, Integrated Wealth Concepts LLC purchased a new position in shares of Qiagen in the second quarter valued at approximately $59,000. Institutional investors and hedge funds own 70.00% of the company’s stock.

About Qiagen

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample technologies, molecular testing solutions and bioinformatics products. The company develops tools that help researchers and healthcare professionals isolate, analyze and interpret biological materials, including DNA, RNA and proteins.

Its portfolio includes laboratory kits and instruments for sample preparation, polymerase chain reaction (PCR), next-generation sequencing, genotyping and molecular diagnostics. QIAGEN also provides digital and bioinformatics solutions used to manage and analyze biological data.